This leads to my old question, hopefully one for the forthcoming 2020 virtual AGM - what happened to MPC-300-IV? It showed evidence of action against both Diabetes [T2] and Rheumatoid Arthritis - two very significant markets and it would seem, given MSB's existing PhIII trials are maturing rapidly, bringing it into the home-straight of clinical development, would now seem logical? I know the Prof himself is particularly exited about what he sees as our potentially, most significant application [pre-Covid]. MPC-300-IV would be application to many diseases.
Maybe MSB see Remestemcel-L as a viable stand-in, in those types of applications used "off label"?
Ulcerative Colitis Clinical Trial, page-8
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.055(5.24%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.13 | $1.04 | $6.781M | 6.207M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 43856 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 66000 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |